Therapeutic Drug Monitoring of Escitalopram in an Outpatient Setting
Authors:
- Margareta ReisMRMargareta Reis
- Maria D ChermáMCMaria D Chermá
- Björn CarlssonBCBjörn Carlsson
- Finn BengtssonFBFinn Bengtsson
- Task Force For Tdm Of Escitalopram In SwedenTSTask Force For Tdm Of Escitalopram In Sweden
- 1 December 2007
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 29 (6) , 758-766
Abstract
The main objectives of this study were to outline the inter- and intraindividual and overall pharmacokinetic variability of S-citalopram, S-desmethylcitalopram, and S-didesmethylcitalopram in serum by means of therapeutic drug monitoring; and to investigate potential correlations between the serum concentration and simultaneously collected clinical data. The study was conducted on outpatients in Sweden in 2002 to 2005. Included in the pharmacokinetic evaluation were 155 patients (68% women and 32% men) aged 17 to 95 years (average, 51 years). One serum sample per patient, taken as a trough value in steady state, was assessed. For the inter- and intraindividual variation calculation, 16 patients were included with two eligible samples each. The median daily dose was 20 mg/day (range, 5-40 mg). Extensive overall serum concentration variability was seen for all dose levels. The interindividual coefficient of variation for dose-normalized concentrations was 71% for S-citalopram, 36% for S-desmethylcitalopram, and 50% for S-didesmethylcitalopram. The intraindividual variations over time for the same parameters were approximately 30%, except for the ratio S-desmethylcitalopram/S-citalopram, which was 23%. The median S-desmethylcitalopram level was approximately 60% of the parent substance and the S-didesmethylcitalopram level approximately 9%. Higher age was correlated with higher serum concentrations, but no gender-related concentration differences were found. A majority (76%) of the patients took one or more drugs in addition to escitalopram, but concomitant medication did not seem to interact with escitalopram. However, women taking oral contraceptives showed a lower metabolic ratio compared with age-matched women. As a result of the wide range of the ratio in this population, these findings are not considered of clinical relevance.Keywords
This publication has 31 references indexed in Scilit:
- The Convergence of Conventional Therapeutic Drug Monitoring and Pharmacogenetic Testing in Personalized Medicine: Focus on AntidepressantsClinical Pharmacology & Therapeutics, 2007
- Inter- and Intraindividual Pharmacokinetic Variations of Mirtazapine and Its N-Demethyl Metabolite in Patients Treated for Major Depressive DisorderTherapeutic Drug Monitoring, 2005
- Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy SwedesBritish Journal of Clinical Pharmacology, 2003
- Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary careInternational Clinical Psychopharmacology, 2003
- Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteersBritish Journal of Clinical Pharmacology, 2001
- Is Therapeutic Drug Monitoring a Case for Optimizing Clinical Outcome and Avoiding Interactions of the Selective Serotonin Reuptake Inhibitors?Therapeutic Drug Monitoring, 2000
- Analysis of Enantiomers of Citalopram and Its Demethylated Metabolites in Plasma of Depressive Patients Using Chiral Reverse-Phase Liquid ChromatographyTherapeutic Drug Monitoring, 1995
- Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLCChirality, 1995
- Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation PolymorphismsTherapeutic Drug Monitoring, 1993
- The pharmacological effect of citalopram resides in the (S)-(+)-enantiomerJournal of Neural Transmission, 1992